Ariceum Therapeutics
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing first-in-class SSTR2 antagonists (satoreotide) for diagnosis and treatment of neuroendocrine tumors and aggressive cancers, with operations across Germany, Switzerland, Australia, UK, and USA.
- Company typePrivate
- Founded2021
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ariceum Therapeutics does
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company founded in 2021 and headquartered in Berlin, Germany, developing targeted radiotherapeutics and diagnostics for neuroendocrine tumors and other aggressive, hard-to-treat cancers. The company's core technology centers on proprietary somatostatin receptor 2 (SSTR2) antagonists, with its lead asset satoreotide (SSO110/SSO120) functioning as a first-in-class theranostic pair radiolabeled with Lutetium-177 for therapy and Gallium-68 for imaging. The pipeline was materially expanded through the June 2023 acquisition of Theragnostics, which added a patented Ga-68 radiopharmaceutical production kit (licensed to Novartis for LOCAMETZ), an Iodine-123-labeled PARP inhibitor (ATT001) in clinical development for glioblastoma, and NEPHROSCAN, an FDA-approved renal imaging diagnostic distributed via GE Healthcare. The lead alpha-emitter program 225Ac-SSO110 received FDA Orphan Drug Designation in February 2025, with a Phase 1/2 trial (SANTANA-225) initiating in November 2025.
The company operates an enterprise field sales model executed through clinical trial sites, hospital cancer centers, and strategic distribution partnerships across Germany, Switzerland, Australia, the UK, and the USA, with isotope supply secured through a multi-isotope agreement with Nusano and a strategic research collaboration with UCB providing access to an mRNA-display peptide discovery platform. Ariceum has dosed over 100 patients with satoreotide and reported a 94.7% disease control rate in its Phase I/II neuroendocrine tumor trial. Revenue mechanics are pre-commercial today, with future revenue expected from a mix of direct product sales (pending regulatory approval), licensing royalties (e.g., Novartis LOCAMETZ), milestone payments, and partnership agreements; the company is privately held with EUR 47.75M in total Series A funding from HealthCap, EQT Life Sciences, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital, and operates with 11-50 employees.
Ariceum Therapeutics firmographics
Firmographics- Name
- Ariceum Therapeutics
- Legal name
- Ariceum Therapeutics GmbH
- Website
- https://ariceum-therapeutics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing first-in-class SSTR2 antagonists (satoreotide) for diagnosis and treatment of neuroendocrine tumors and aggressive cancers, with operations across Germany, Switzerland, Australia, UK, and USA.
- Ownership category
- akta.pro rank
Ariceum Therapeutics industry classification
Industry- Product category
- Radiopharmaceuticals / Targeted Radiotherapy
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)
Keywords
Where Ariceum Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices5 records
Markets served
Ariceum Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Radiopharmaceutical Drug Development and Commercialization: As a clinical-stage company, Ariceum is focused on developing and commercializing its pipeline of targeted radiotherapeutics. Revenue will be generated through product sales upon regulatory approval, as well as potential licensing agreements and partnerships with larger pharmaceutical companies.
- Licensing and Partnership Revenue: The company generates licensing revenue through technology licensing agreements, such as the Ga-68 kit technology licensed to Novartis for LOCAMETZ, and potential future co-development partnerships.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Ariceum Therapeutics product offering
Product offeringCore offering
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing targeted systemic radiotherapy (STR) products that combine diagnostic imaging and targeted radiotherapy to visualize and treat neuroendocrine tumors and other aggressive cancers. Its lead programs include the SSTR2 antagonist satoreotide (Lu-177/Ga-68 theranostic pair), the alpha-emitter 225Ac-SSO110, the PARP inhibitor Auger therapy 123I-ATT001, and the FDA-approved renal imaging diagnostic NEPHROSCAN distributed via GE Healthcare.
Differentiator
Problem solved
Functional benefit
Brands
- NephroScan: FDA-approved diagnostic product for renal parenchymal disorders, partnered with GE Healthcare.
Products and services
- Satoreotide (SSO110/SSO120) - 177Lu-Satoreotide / 68Ga-Satoreotide First-in-class and best-in-class somatostatin receptor 2 (SSTR2) antagonist radiolabeled with Lutetium-177 for therapy and Gallium-68 for imaging, functioning as a theranostic pair for diagnosis and treatment of neuroendocrine tumors and SSTR2-positive cancers. Being evaluated for neuroendocrine tumors, ES-SCLC, and Merkel Cell Carcinoma. Over 100 patients dosed across early clinical trials.
- 225Ac-SSO110 (Actinium-225 labeled Satoreotide) First SSTR2 antagonist radioligand therapy in clinical development using Actinium-225 alpha radiation, for targeted alpha therapy of extensive-stage small cell lung cancer (ES-SCLC) and Merkel Cell Carcinoma (MCC). Delivers high linear energy transfer alpha particles directly to SSTR2-expressing tumor cells.
- ATT001 (123I-ATT001) - Iodine-123 labeled PARP Inhibitor Iodine-123 radiolabeled PARP inhibitor for Auger electron therapy, delivering targeted subcellular radiotherapy to cancer cells expressing PARP enzyme while sparing healthy tissue. In clinical development for recurrent glioblastoma and other solid tumors.
- NEPHROSCAN FDA-approved diagnostic radiopharmaceutical product for renal scintigraphic imaging used by nuclear medicine and radiology departments for diagnosis of renal parenchymal disorders. Currently commercialized and distributed in the United States via GE Healthcare.
- Gallium-68 (Ga-68) Radiopharmaceutical Production Kit Single-vial, single-step Ga-68 kit technology enabling production of multiple doses of Ga-68 radiopharmaceuticals. Licensed to Novartis for the LOCAMETZ PSMA kit; serves as a platform for generating diagnostic imaging agents.
Quantifiable outcome
- 94.7% disease control rate in neuroendocrine tumor patients (Phase I/II trial, 38 evaluable patients)
- +2 more outcomes
Companies that use Ariceum Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Ariceum Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ariceum Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- NusanocoreMulti-isotope supply agreement providing Ariceum access to Nusano-produced radioisotopes including actinium-225 (Ac-225) and lutetium-177 (Lu-177) to support the company's radiotherapeutic pipeline including 225Ac-SSO110 currently in Phase 1/2 trials for small cell lung cancer and Merkel Cell Carcinoma.
- Eurofins CDMOcoreStrategic partnership where Eurofins CDMO provides Clinical Trial Supply services including Qualified Person release of Drug Substance into Europe, storage, cold chain management, packaging, and delivery of Drug Product to investigational sites for Ariceum's Phase I/II clinical studies.
- GE HealthcarecorePartnership for NEPHROSCAN, an FDA-approved diagnostic product for renal scintigraphic imaging. GE Healthcare distributes NEPHROSCAN in the United States through their radiopharmacy network.
- UCBflagshipExclusive strategic research collaboration to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases. UCB provides access to its mRNA-display technology platform ExtremeDiversity for peptide discovery, while Ariceum provides radiopharmaceutical and labeling expertise.
- GenesisCarecoreClinical trial partnership for Phase Ib study of satoreotide in extensive-stage small cell lung cancer at the GenesisCare Murdoch Theranostics and Molecular Imaging Centre in Perth, Australia.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Ariceum Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Novartis: Pharmaceutical leader with LUTATHERA (SSTR2 agonist, direct competitor to satoreotide) and PLUVICTO (PSMA-targeted RLT). Validates the radiopharmaceutical market opportunity and licenses Ariceum's Ga-68 kit technology for LOCAMETZ.
- Bayer: Diversified pharma with established radiopharmaceutical franchise (Xofigo/radium-223) and active investments in actinium-225 production and next-generation targeted radionuclide therapies, overlapping with Ariceum's therapeutic pipeline.
- Ipsen: Specialty pharma that originally developed satoreotide before divesting rights to Ariceum in 2021. Remains a shareholder and is a broad oncology incumbent with overlapping interest in neuroendocrine tumor treatments.
Direct peers
- Lantheus Holdings: Radiopharmaceutical company with PYLARIFY (Piflufolastat F-18), a PSMA-targeted PET imaging agent. Direct comparable in the radiopharmaceutical oncology imaging and therapy space, particularly for prostate cancer diagnostics.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing Illuccix (Ga-68 PSMA-11) for prostate cancer imaging. Direct competitor in Ga-68 PSMA imaging space and broader theranostic oncology strategy.
- ITM Isotope Technologies: Munich-based radiopharmaceutical company developing targeted radionuclide therapies for various solid tumors. Closely comparable in European radiopharmaceutical development, particularly in Lu-177 and other therapeutic isotopes.
- Fusion Pharmaceuticals: Alpha-emitter radiopharmaceutical company developing Actinium-225 targeted therapies for solid tumors (acquired by AstraZeneca in 2024). Highly comparable to Ariceum's 225Ac-SSO110 alpha-therapy approach and target indications.
- POINT Biopharma: Clinical-stage radiopharmaceutical company developing PNT2002 (Lu-177 PSMA) and PNT2003 (Lu-177 DOTATATE) for prostate and neuroendocrine cancers (acquired by Eli Lilly in 2023). Direct comparable in Lu-177-based RLT development.
- RayzeBio: Actinium-225-based radiopharmaceutical company developing alpha-emitter therapies for solid tumors (acquired by Bristol-Myers Squibb in 2024). Highly comparable alpha-emitter strategy and therapeutic radionuclide development approach.
Emerging players
- Aktis Oncology: Clinical-stage radiopharmaceutical company developing targeted alpha therapies for solid tumors. Emerging peer with overlapping alpha-emitter approach and similar early-stage clinical positioning to Ariceum.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Ariceum Therapeutics social profiles
Digital presenceAriceum Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ariceum Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Ariceum Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Ariceum Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ariceum Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ariceum Therapeutics
What does Ariceum Therapeutics do?
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing targeted systemic radiotherapy (STR) products that combine diagnostic imaging and targeted radiotherapy to visualize and treat neuroendocrine tumors and other aggressive cancers. Its lead programs include the SSTR2 antagonist satoreotide (Lu-177/Ga-68 theranostic pair), the alpha-emitter 225Ac-SSO110, the PARP inhibitor Auger therapy 123I-ATT001, and the FDA-approved renal imaging diagnostic NEPHROSCAN distributed via GE Healthcare.
Is Ariceum Therapeutics a public or private company?
Ariceum Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ariceum Therapeutics founded?
Ariceum Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Ariceum Therapeutics based?
Ariceum Therapeutics is headquartered in Berlin, Germany, in the Europe region.
How does Ariceum Therapeutics make money?
Two revenue lines are on record. Radiopharmaceutical Drug Development and Commercialization is the primary driver. The others are licensing and Partnership Revenue.
Who are Ariceum Therapeutics's main competitors?
Broad incumbents on record are Novartis, Bayer and Ipsen. Direct peers are Lantheus Holdings, Telix Pharmaceuticals, ITM Isotope Technologies, Fusion Pharmaceuticals, POINT Biopharma and RayzeBio. Aktis Oncology is listed as an emerging player.
Does Ariceum Therapeutics have an API?
No public API is recorded for Ariceum Therapeutics.
What industry is Ariceum Therapeutics in?
Ariceum Therapeutics's product category is Radiopharmaceuticals / Targeted Radiotherapy. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 5417 and its SIC code is 2835.